During the third quarter, Bank Pictet & Cie Europe AG increased its stake in Gilead Sciences by 502.8%, acquiring an additional 12,752 shares to bring its total holding to 15,288 shares valued at $1.697 million. This move follows significant purchases in the second quarter by other major institutions: Invesco Ltd. added 3.39 million shares (a 33.5% increase), Sivik Global Healthcare LLC added 10,000 shares (25.0%), One Wealth Advisors LLC purchased 2,364 shares (34.8%), and Lombard Odier Asset Management Switzerland SA acquired 10,535 shares (24.6%). Jump Financial LLC also initiated a new position worth approximately $6.99 million. Collectively, institutional investors now own 83.67% of Gilead’s outstanding shares, underscoring renewed confidence in the company’s cash-flow profile and long-term growth prospects.

Gilead Sciences reported third-quarter revenue of $7.77 billion, a 3.0% increase year-over-year, and adjusted EPS of $2.47, surpassing consensus estimates by $0.31. The company achieved a net margin of 27.9% and a return on equity of 51.9%. Driven by strong antiviral and emerging oncology franchise performance, management set full-year 2025 EPS guidance between $8.05 and $8.25. Equities analysts remain broadly positive: two firms maintain strong-buy recommendations, 22 hold buy ratings, and four rate the shares as a hold. The average analyst target implies upside potential based on current consensus forecasts of $7.95 EPS for the current fiscal year.

Gilead declared a quarterly dividend of $0.79 per share, marking an annualized payout of $3.16 and a yield of 2.6%, with a payout ratio of 48.99%. The distribution on December 30th followed a record date of December 15th. In insider activity, CFO Andrew D. Dickinson sold 3,000 shares for proceeds of $366,000 and Director Jeffrey Bluestone disposed of 5,000 shares for $625,400, representing decreases of 1.92% and 35.92% in their personal holdings, respectively. Over the last quarter, insiders have sold a total of 136,257 shares valued at $16.86 million, while maintaining collective ownership of 0.27% of the outstanding shares.